NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has published two new rapid COVID-19 guidelines. (Source: NHS Networks)
Source: NHS Networks - May 19, 2020 Category: UK Health Source Type: news

COVID-19 rapid guideline: interstitial lung disease [NG177], NICE
The guideline provides clinicians with advice on how to adjust care to reduce patients'exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic. The guideline highlights that bronchoscopy and pulmonary function tests have the potential to spread COVID-19 and they should only be carried out if the patient urgently needs them and if the results will have a direct impact on their care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 18, 2020 Category: Consumer Health News Source Type: news

VIDA Completes Second Close Of Round C Financing
CORALVILLE, Iowa, April 15, 2020 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as a s... Devices, Venture Capital VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news

High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis
The first evidence-based consensus statements for systemic sclerosis-associated interstitial lung disease (SSc-ILD) recommend use of high-resolution computed tomography (CT) for screening and diagnosis, and offer guidance on when to initiate or escalate emerging treatment options.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 4, 2020 Category: Radiology Tags: Rheumatology News Source Type: news

$20 million fundraising effort will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on ident...
Source: UCLA Newsroom: Health Sciences - November 15, 2019 Category: Universities & Medical Training Source Type: news

$20 million fundraising initiative will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on ident...
Source: UCLA Newsroom: Health Sciences - November 15, 2019 Category: Universities & Medical Training Source Type: news

FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
The designation was supported by results from the Phase III INBUILD® study that met its primary endpoint and was recently published in the New England Journal of Medicine RIDGEFIELD, Conn., Oct. 10, 2019 -- (Healthcare Sales & Marketing Network) --... Biopharmaceuticals, FDA Boehringer Ingelheim, Ofev, nintedanib, interstitial lung disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 10, 2019 Category: Pharmaceuticals Source Type: news

VIDA Expands Board, Announcing Erkan Akyuz As Independent Director
CORALVILLE, Iowa, Oct. 4, 2019 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, today announced the appointment of Erkan Akyuz as independent director. Mr. Akyuz will j... Devices, Radiology, Oncology, Personnel VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2019 Category: Pharmaceuticals Source Type: news

Nintedanib Slows Fibrosing Interstitial Lung Disease
MONDAY, Sept. 30, 2019 -- For patients with progressive fibrosing interstitial lung diseases, nintedanib is associated with a lower rate of decline in forced vital capacity (FVC) compared with placebo, according to a study published online Sept. 29... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves First Treatment, Ofev (Nintedanib), for ILD With Systemic Sclerosis, Scleroderma
MONDAY, Sept. 9, 2019 -- The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), the agency... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2019 Category: General Medicine Source Type: news

FDA OKs Nintedanib (Ofev) for Rare Lung Disease FDA OKs Nintedanib (Ofev) for Rare Lung Disease
Nintedanib capsules are approved for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease.News Alerts (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 9, 2019 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

FDA approves first treatment for patients with rare type of lung disease
The U.S. Food and Drug Administration has approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition. (Source: World Pharma News)
Source: World Pharma News - September 9, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
September 06, 2019 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 6, 2019 Category: Drugs & Pharmacology Source Type: news

Trump Signs 9/11 Victims Fund Extension
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092. During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States. The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families. The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - July 29, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Panel Recommends Nintedanib for Rare Lung Disease FDA Panel Recommends Nintedanib for Rare Lung Disease
Small effect size for primary endpoint in systemic sclerosis-associated interstitial lung disease study, and lack of significant difference between groups for secondary outcomes, were sticking points.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - July 26, 2019 Category: Rheumatology Tags: Rheumatology News Source Type: news

Senate Passes 9/11 Victim Compensation Fund Extension
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092. The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell. According to World Trade Center R...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

9/11 Victims Fund Passes Senate
The Senate gallery erupted in applause from politicians and first responders on Tuesday after a 97-2 vote to extend the September 11 Victim Compensation Fund until 2092. The reauthorization will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension will allow victims and their families to file claims through 2090, but they will be paid out through 2092. The extension of funding will benefit victims who may develop mesothelioma linked to ...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

A Pro-Con Debate on How to Care for Patients With Interstitial Lung Disease
DALLAS--Which patients are candidates for antifibrotic therapy? Is extracorporeal membrane oxygenation appropriate for all ILD patients? The topics were hotly debated on Monday at the American Thoracic Society meeting.   (Source: ConsultantLive)
Source: ConsultantLive - May 21, 2019 Category: Internal Medicine Authors: Christina Bennett, MS Tags: Conferences/ATS Source Type: news

nintedanib slows pulmonary function loss in people with ssc-ild
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1Results of pivotal Phase III SENSCIS ®trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USAInterstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3FDA grants priority review to application for regulatory approval for nintedanib in patients ...
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news

Pembrokeshire girl, 10, dies waiting for lung transplant
Belle Curran won numerous bravery awards as she battled with rare Interstitial Lung Disease. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 7, 2019 Category: Consumer Health News Source Type: news

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF). (Source: World Pharma News)
Source: World Pharma News - March 26, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need ... Biopharmaceuticals, FDA, Regulatory Boehringer Ingelheim, nintedanib, interstitial lung disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2019 Category: Pharmaceuticals Source Type: news

FDA-and-EMA-regulatory-submission-nintedanib-in-SSc-ILD
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILDSystemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue diseasePulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 15, 2019 Category: Research Source Type: news

Complex Dosing, Polypharmacy Common With Interstitial Lung Disease
Patients receiving systemic corticosteroids are at high risk for drug - disease interactions (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 14, 2019 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Journal, Source Type: news

Complex Dosing, Polypharmacy Common With Interstitial Lung Disease
THURSDAY, March 14, 2019 -- Polypharmacy and complex medication regimens are common in patients with interstitial lung disease (ILD), according to a study published online Feb. 20 in Respirology. Yet H. Khor, M.B.B.S., Ph.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2019 Category: Pharmaceuticals Source Type: news

COPD, ILD Patients May Not Benefit From Bilateral Lung Transplant Listing
MONDAY, March 4, 2019 -- While an unrestricted listing strategy does not seem to impact overall survival among patients with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) awaiting lung transplant, it may increase... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 4, 2019 Category: Pharmaceuticals Source Type: news

Pulmonary Disease Rates High in Lupus
(MedPage Today) -- Interstitial lung disease most common among incident, prevalent cases (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 8, 2019 Category: Primary Care Source Type: news

After the Product-Centric Medical Industry – What’s Next?
For decades, the medical device industry has reaped rewards by providing new technologies and solutions that improve healthcare delivery. Now, more than 8000 new medical devices enter the U.S. market each year1 as the industry faces sweeping changes that will not only impact the life cycle of many existing products, but also future innovations. New payment models, patients replacing physicians as stewards of their care, a changing regulatory framework, and data as a central solution to implement these strategies are all converging trends requiring medical device makers to prepare their organizations to adapt to...
Source: MDDI - January 25, 2019 Category: Medical Devices Authors: David Hahn Tags: Digital Health Source Type: news

Bittersweet Ending to Asbestos Cleanup in Libby, Montana
The asbestos cleanup of Libby, Montana, is coming to a celebrated close. The U.S. Environmental Protection Agency will soon end the largest, longest-running asbestos cleanup project in American history. It’s a bittersweet ending to what is left behind. The 19-year, $600 million EPA Superfund project aimed to right the wrongs created by the shuttered W.R. Grace and Co. vermiculite mine. Once the lifeblood of the community, it also became a cold-hearted killer. Although the mine was closed almost 30 years ago, health officials have since documented more than 400 deaths linked to asbestos-related diseases such as mes...
Source: Asbestos and Mesothelioma News - December 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Does She Have SCID?
Discussion Severe-combined immunodefiency (SCID) is actually a group of inherited disorders with an absence or dysfunction of T, B and NK cells that results in severe dysfunction of the immune system. SCID is a primary immunodeficiency. SCID was thought to be a rare disorder but with the advent of neonatal screening the incidence in the US general population is estimated at ~1 in 58,000 live births, but with numbers higher or lower depending on the specific population. Patients often have failure to thrive, oral candidiasis, and diarrhea as infants as well as a variety of infectious diseases. They can also have interstit...
Source: PediatricEducation.org - December 3, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Paradoxical Development of Panuveitis and Granulomatous Interstitial Lung Disease Associated with Adalimumab Therapy for Psoriasis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

CU researchers find common genetic link in lung ailments
(University of Colorado Anschutz Medical Campus) An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. The findings are published in the current issue of the New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: How can psoriasis affect the lungs?
Psoriasis causes widespread inflammation that can affect the skin and several organ systems. A person with psoriasis may experience lung-related complications, including lung fibrosis and interstitial lung disease. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2018 Category: Consumer Health News Tags: Psoriasis Source Type: news

Low Vitamin D Levels Tied to Interstitial Lung Disease
Findings include both high - attenuation areas, interstitial lung abnormalities on scans (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 21, 2018 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Pulmonology, Journal, Source Type: news

Low Vitamin D Levels Tied to Interstitial Lung Disease
FRIDAY, Sept. 21, 2018 -- Vitamin D deficiency is independently associated with subclinical interstitial lung disease (ILD) and its progression, according to a study recently published in the Journal of Nutrition. Samuel M. Kim, M.D., from the Johns... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 21, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: What to know about rheumatoid lung disease
Rheumatoid lung disease happens when rheumatoid arthritis (RA) affects a person's lungs. Lung issues arise in around 10 percent of people with RA, including interstitial lung disease or lung nodules. In this article, we give an overview of rheumatoid lung disease, including symptoms, treatments, and life expectancy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 28, 2018 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

Researchers Find Link Between Vitamin D and Asbestosis
This study was not designed to explain whether supplementing with vitamin D will protect against asbestosis. This new research also does not examine if taking vitamin D will slow down the progression of existing ILD. Still, there are a lot of good reasons to pay attention to the sunshine vitamin. Regardless of whether a person has been exposed to asbestos, no one should ignore very low vitamin D levels. People already diagnosed with an asbestos-related cancer, may benefit from a quick check of vitamin D levels. According to the medical literature, up to 80 percent of people with cancer may be vitamin D deficient. People ca...
Source: Asbestos and Mesothelioma News - July 16, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Vitamin D Deficiency Could Be Lung Disease Risk
MONDAY, June 25, 2018 -- Low levels of vitamin D are associated with an increased risk of a disease that causes lung inflammation and scarring, researchers say. About 200,000 cases of interstitial lung disease (ILD) are diagnosed each year in the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 25, 2018 Category: General Medicine Source Type: news

Low vitamin D linked to scarring lung disease
Lower than normal levels of vitamin D in the blood were linked to increased risk of early interstitial lung disease, according to an analysis of a new study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 19, 2018 Category: Consumer Health News Source Type: news

Low vitamin D levels associated with scarring lung disease
(Johns Hopkins Medicine) Reviewing medical information gathered on more than 6,000 adults over a 10-year period, Johns Hopkins researchers have found that lower than normal blood levels of vitamin D were linked to increased risk of early signs of interstitial lung disease (ILD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 19, 2018 Category: International Medicine & Public Health Source Type: news

Barriers to Timely Diagnosis of Interstitial Lung Disease Barriers to Timely Diagnosis of Interstitial Lung Disease
What are the barriers patients with interstitial lung diseases may face in obtaining a timely and accurate diagnosis?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA's Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner. (Source: World Pharma News)
Source: World Pharma News - March 19, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Lung Disease Common in Late-Onset SLE (CME/CE)
(MedPage Today) -- Rates of interstitial lung disease more than doubled (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2018 Category: Primary Care Source Type: news

Medical News Today: What to know about interstitial lung disease
A look at interstitial lung disease, a group of diseases that make it difficult to get enough oxygen. Included is detail on types and complications. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 18, 2018 Category: Consumer Health News Tags: Pulmonary System Source Type: news

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news

Exercise Training in Interstitial Lung Disease Exercise Training in Interstitial Lung Disease
Pulmonary rehabilitation programs including exercise training may be an effective intervention in stable patients with interstitial lung disease.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Warning of too few specialist nurses for incurable lung disease
A lack of access to specialist nurses is an important factor contributing to a crisis in care for patients with interstitial lung disease (ILD), according to a charity report. (Source: Nursing Times)
Source: Nursing Times - September 18, 2017 Category: Nursing Source Type: news

Interstitial Pneumonitis (Interstitial Lung Disease)
Title: Interstitial Pneumonitis (Interstitial Lung Disease)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - August 8, 2017 Category: Respiratory Medicine Source Type: news

Occupational Exposures Linked to Interstitial Lung Disease
Job exposure matrix score increase in vapors, gas, dust, fumes exposure ups high attenuation areas (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 7, 2017 Category: Respiratory Medicine Tags: Pulmonology, Journal, Source Type: news